<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nagai J</submitter><funding>NICHD NIH HHS</funding><funding>NIDA NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>Medical Research Council</funding><funding>NINDS NIH HHS</funding><pagination>2256-2274.e9</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8418870</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>109(14)</volume><pubmed_abstract>Astrocytes respond to neurotransmitters and neuromodulators using G-protein-coupled receptors (GPCRs) to mediate physiological responses. Despite their importance, there has been no method to genetically, specifically, and effectively attenuate astrocyte G&lt;sub>q&lt;/sub> GPCR pathways to explore consequences of this prevalent signaling mechanism in vivo. We report a 122-residue inhibitory peptide from β-adrenergic receptor kinase 1 (iβARK; and inactive D110A control) to attenuate astrocyte G&lt;sub>q&lt;/sub> GPCR signaling. iβARK significantly attenuated G&lt;sub>q&lt;/sub> GPCR Ca&lt;sup>2+&lt;/sup> signaling in brain slices and, in vivo, altered behavioral responses, spared other GPCR responses, and did not alter astrocyte spontaneous Ca&lt;sup>2+&lt;/sup> signals, morphology, electrophysiological properties, or </pubmed_abstract><journal>Neuron</journal><pubmed_title>Specific and behaviorally consequential astrocyte G&lt;sub>q&lt;/sub> GPCR signaling attenuation in vivo with iβARK.</pubmed_title><pmcid>PMC8418870</pmcid><funding_grant_id>R35 NS111583</funding_grant_id><funding_grant_id>R01 DA047444</funding_grant_id><funding_grant_id>R00 HL132882</funding_grant_id><funding_grant_id>UKDRI-4007</funding_grant_id><funding_grant_id>U54 HD087101</funding_grant_id><funding_grant_id>K99 HL132882</funding_grant_id><funding_grant_id>P30 NS062691</funding_grant_id><funding_grant_id>R01 NS116589</funding_grant_id><pubmed_authors>Gangwani MR</pubmed_authors><pubmed_authors>Gradinaru V</pubmed_authors><pubmed_authors>Nagai J</pubmed_authors><pubmed_authors>Schumacher SM</pubmed_authors><pubmed_authors>Diaz-Castro B</pubmed_authors><pubmed_authors>Bellafard A</pubmed_authors><pubmed_authors>Qu Z</pubmed_authors><pubmed_authors>Khakh BS</pubmed_authors><pubmed_authors>Golshani P</pubmed_authors><pubmed_authors>Coppola G</pubmed_authors><pubmed_authors>Yu X</pubmed_authors><pubmed_authors>Ollivier M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Specific and behaviorally consequential astrocyte G&lt;sub>q&lt;/sub> GPCR signaling attenuation in vivo with iβARK.</name><description>Astrocytes respond to neurotransmitters and neuromodulators using G-protein-coupled receptors (GPCRs) to mediate physiological responses. Despite their importance, there has been no method to genetically, specifically, and effectively attenuate astrocyte G&lt;sub>q&lt;/sub> GPCR pathways to explore consequences of this prevalent signaling mechanism in vivo. We report a 122-residue inhibitory peptide from β-adrenergic receptor kinase 1 (iβARK; and inactive D110A control) to attenuate astrocyte G&lt;sub>q&lt;/sub> GPCR signaling. iβARK significantly attenuated G&lt;sub>q&lt;/sub> GPCR Ca&lt;sup>2+&lt;/sup> signaling in brain slices and, in vivo, altered behavioral responses, spared other GPCR responses, and did not alter astrocyte spontaneous Ca&lt;sup>2+&lt;/sup> signals, morphology, electrophysiological properties, or </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2026-05-09T03:09:25.177Z</modification><creation>2025-04-05T14:08:24.204Z</creation></dates><accession>S-EPMC8418870</accession><cross_references><pubmed>34139149</pubmed><doi>10.1016/j.neuron.2021.05.023</doi></cross_references></HashMap>